Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.80 |
| ▸ | KDR | P35968 | 6/20 | 0.80 |
| ▸ | RET | P07949 | 6/20 | 0.80 |
| ▸ | LCK | P06239 | 2/20 | 0.78 |
| ▸ | RAF1 | P04049 | 2/20 | 0.72 |
| ▸ | BRAF | P15056 | 2/20 | 0.72 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.72 |
| ▸ | AURKA | O14965 | 2/20 | 0.72 |
| ▸ | KIF5B | P33176 | 3/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.68 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | STK10 | O94804 | 1/20 | 0.68 |
| ▸ | FLT3 | P36888 | 1/20 | 0.68 |
| ▸ | JAK3 | P52333 | 1/20 | 0.68 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.68 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.68 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.68 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.68 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.68 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604745 | 0.96 | EGFR (0.82) | EGFRKDRRETLCKRAF1 | |
| SCHEMBL29515328 | 0.89 | EGFR (1.00) | EGFRKDRRETLCKKIF5B | |
| SCHEMBL1257431 | 0.89 | EGFR (1.00) | EGFRKDRRETLCKKIF5B | |
| SCHEMBL15051719 | 0.89 | BRAF (0.83) | EGFRKDRRETLCKRAF1 | |
| Hydrochloric Acid SCHEMBL5475737 | 0.88 | EGFR (1.00) | EGFRKDRRETLCKRIPK2 | |
| SCHEMBL3241479 | 0.88 | KDR (0.82) | EGFRKDRRETRAF1BRAF | |
| SCHEMBL2102382 | 0.88 | EGFR (0.82) | EGFRKDRRETLCKRAF1 | |
| SCHEMBL14964757 | 0.87 | EGFR (0.81) | EGFRKDRRETLCKRAF1 | |
| SCHEMBL5242610 | 0.87 | KDR (0.81) | EGFRKDRRETLCKRAF1 | |
| SCHEMBL3527282 | 0.87 | AURKB (0.94) | EGFRKDRAURKBAURKAIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| WO-2016123706-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-8735410-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-05-08 | — | — | US | disclosed |
| US-20110152297-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Astra Zeneca AB Corporation | 2011-06-23 | — | — | US | disclosed |
| EP-1680426-B1 | 1.3.4-TRIAZA-PHENALENE AND 1,3,4,6-TETRAAZAPHENALENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-7217717-B2 | Phenalene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217717-B2 | Phenalene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217717-B2 | Phenalene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070032513-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1680426-A1 | 1.3.4-TRIAZA-PHENALENE AND 1,3,4,6-TETRAAZAPHENALENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| WO-2004111055-A1 | 1.3.4-TRIAZA-PHENALENE AND 1,3,4,6-TETRAAZAPHENALENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20040254205-A1 | Phenalene derivatives | LUK KIN-CHUN (US) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | EGFR, ERBB2, ERBB4 | EGFR 1/4885KDR 339/4885RET 49/4885 |
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | EGFR 2929/4885KDR 2610/4885RET 1558/4885 |
| US-20070032513-A1 | Quinazoline derivatives | ERBB2, EGFR, ABL1 | EGFR 2/4885KDR 124/4885RET 56/4885 |
| US-20110152297-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | EGFR 3/4885KDR 73/4885RET 7/4885 |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | EGFR 2929/4885KDR 2610/4885RET 1558/4885 |
| US-20040254205-A1 | Phenalene derivatives | EGFR, ERBB2, ERBB4 | EGFR 1/4885KDR 504/4885RET 10/4885 |
| US-20140128612-A1 | DEUTERATED OMEGA DIPHENYLUREA RELATED COMPOUNDS AND INTERMEDIATES | PNLIP, PDXK, DGKK | EGFR 3102/4885KDR 3962/4885RET 2996/4885 |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ERBB2, ABL1, EGFR | EGFR 3/4885KDR 180/4885RET 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.